Narrative updates are currently in beta.

Back to narrative

Update shared on15 Aug 2025

AnalystConsensusTarget's Fair Value
US$3.25
36.9% undervalued intrinsic discount
15 Aug
US$2.05
Loading
1Y
-16.0%
7D
15.2%

As 3D Systems’ net profit margin and revenue growth forecasts remain unchanged at 0.72% and -4.5% respectively, the analyst consensus price target is also maintained at $3.25.


What's in the News


  • 3D Systems launched the NextDent Jetted Denture Solution and NextDent 300 MultiJet printer in the U.S., enabling rapid, post-cure-free, single-piece, dual-material dentures with improved aesthetics and durability.
  • The company’s bioprinting technology enabled FDA approval (De Novo) for a fully bioabsorbable, sutureless peripheral nerve repair device (COAPTIUM CONNECT with TISSIUM Light), developed with TISSIUM.
  • A class action lawsuit alleges 3D Systems made false and misleading statements regarding customer demand, milestone-driven revenue recognition, and the impact on its Regenerative Medicine Program.
  • 3D Systems reported weak Q4 2024 and Q1 2025 financials, withdrew its FY25 outlook due to macro headwinds and dental segment challenges, leading to sharp share price declines.
  • The company completed a $92M convertible note private placement with a 5.875% interest rate and an initial conversion premium of 20%.

Valuation Changes


Summary of Valuation Changes for 3D Systems

  • The Consensus Analyst Price Target remained effectively unchanged, at $3.25.
  • The Net Profit Margin for 3D Systems remained effectively unchanged, at 0.72%.
  • The Consensus Revenue Growth forecasts for 3D Systems remained effectively unchanged, at -4.5% per annum.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.